You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,555,993


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,555,993 protect, and when does it expire?

Patent 10,555,993 protects TECFIDERA and is included in one NDA.

This patent has twelve patent family members in six countries.

Summary for Patent: 10,555,993
Title:Dimethyl fumarate and vaccination regimens
Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
Inventor(s): Viglietta; Vissia (Boston, MA)
Assignee: Biogen MA Inc. (Cambridge, MA)
Application Number:16/391,583
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,555,993
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,555,993

Introduction

United States Patent 10,555,993, titled "Dimethyl fumarate and vaccination regimens," is a patent that combines medical treatment and vaccination protocols, specifically targeting multiple sclerosis. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Publication Number and Authority The patent, US10555993B2, was granted by the United States Patent and Trademark Office (USPTO) and is part of the US patent system[4].

Prior Art and Background

The patent builds on existing knowledge in the fields of immunology and pharmacology, particularly focusing on the use of dimethyl fumarate (DMF) in conjunction with vaccination regimens. Prior art keywords include "vaccine," "dose," "fumarate," and "multiple sclerosis," indicating the patent's roots in these areas[4].

Claims Analysis

Independent and Dependent Claims

The patent includes both independent and dependent claims. Independent claims define the invention's core aspects, while dependent claims elaborate on or modify the independent claims.

  • Independent Claims: These claims outline the primary method of treating or preventing multiple sclerosis using DMF and vaccination regimens. For example, Claim 1 might describe the method of administering DMF in combination with a vaccine to a patient[4].

  • Dependent Claims: These claims provide additional details or variations of the independent claims. For instance, a dependent claim might specify the type of vaccine used (e.g., pneumovax 23) or the dosage regimen of DMF[4].

Claim Scope and Breadth

The scope of the claims is crucial in determining the patent's breadth and potential impact. Research suggests that narrower claims at publication are associated with a higher probability of grant and a shorter examination process than broader claims[5].

  • Independent Claim Length and Count: Metrics such as independent claim length and count can be used to measure patent scope. Shorter, more focused independent claims generally indicate a narrower scope, which can be beneficial in terms of clarity and validity[5].

Patent Scope and Quality

Metrics for Measuring Scope

The patent scope can be evaluated using metrics like independent claim length and count. These metrics have been validated to have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes[5].

  • Patent Maintenance Payments: Patents with narrower claims tend to have lower maintenance payments, indicating a more focused and potentially higher-quality patent[5].

  • Forward Citations: The number of forward citations can indicate the patent's impact and relevance. Patents with narrower claims may receive more forward citations due to their clarity and specificity[5].

Examination Process

The examination process for this patent would have involved a thorough review of the claims to ensure they meet the criteria of novelty, non-obviousness, and utility.

  • Office Actions and Responses: The Patent Examination Data System (PEDS) could provide insights into the examination process, including any office actions and the applicant's responses. This data can help understand how the claims were refined during the examination process[1].

International and Global Context

Global Patent Family

The Global Dossier service provided by the USPTO allows users to view the patent family for a specific application, including related applications filed at participating IP Offices. This can help in understanding the global reach and protection of the invention[1].

  • International Patent Offices: Searching databases from other international intellectual property offices, such as the European Patent Office (EPO) or the World Intellectual Property Organization (WIPO), can reveal if similar patents have been filed or granted in other jurisdictions[1].

Economic and Practical Implications

Licensing and Litigation

The clarity and breadth of the patent claims can significantly impact licensing and litigation costs. Narrower, well-defined claims can reduce the likelihood of disputes and make licensing agreements more straightforward[5].

  • Innovation Incentives: The quality of the patent, as measured by its scope and clarity, can influence innovation incentives. Clear and valid patents can encourage further innovation by providing a clear landscape for other inventors and companies[5].

Key Takeaways

  • Claims Analysis: The patent includes both independent and dependent claims, with a focus on the method of treating or preventing multiple sclerosis using DMF and vaccination regimens.
  • Patent Scope: The scope of the claims is crucial, with narrower claims generally associated with higher grant probabilities and shorter examination processes.
  • Global Context: The patent's global reach can be understood through services like the Global Dossier and international patent office databases.
  • Economic Implications: The clarity and breadth of the claims can impact licensing and litigation costs, as well as innovation incentives.

FAQs

Q: What is the main focus of United States Patent 10,555,993? A: The main focus is on a method of treating or preventing multiple sclerosis using dimethyl fumarate (DMF) in combination with vaccination regimens.

Q: How can the scope of a patent be measured? A: The scope of a patent can be measured using metrics such as independent claim length and count, which have been validated to have explanatory power for several correlates of patent scope.

Q: What is the significance of the Global Dossier service in patent searching? A: The Global Dossier service allows users to view the patent family for a specific application, including related applications filed at participating IP Offices, providing insights into the global reach and protection of the invention.

Q: How do narrower claims impact the examination process? A: Narrower claims are associated with a higher probability of grant and a shorter examination process compared to broader claims.

Q: What are the economic implications of clear and valid patent claims? A: Clear and valid patent claims can reduce licensing and litigation costs and encourage further innovation by providing a clear landscape for other inventors and companies.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. ACUS - U.S. Patent Small Claims Court: https://www.acus.gov/research-projects/us-patent-small-claims-court
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. Google Patents - US10555993B2: https://patents.google.com/patent/US10555993B2/en
  5. SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,555,993

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 AB RX Yes No 10,555,993 ⤷  Subscribe METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 AB RX Yes Yes 10,555,993 ⤷  Subscribe METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,555,993

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016244325 ⤷  Subscribe
Australia 2018229422 ⤷  Subscribe
Australia 2020213345 ⤷  Subscribe
Australia 2022221548 ⤷  Subscribe
Canada 2942690 ⤷  Subscribe
European Patent Office 3116536 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.